PDF(Pubmed)
Abstract：
The potential relationship between diabetes and COVID-19 has been evaluated. However, new knowledge is rapidly emerging. In this study, we systematically reviewed the relationship between viral cell surface receptors (ACE2, AXL, CD147, DC-SIGN, L-SIGN and DPP4) and SARS-CoV-2 infection risk, and emphasized the implications of ACE2 on SARS-CoV-2 infection and COVID-19 pathogenesis. Besides, we updated on the two-way interactions between diabetes and COVID-19, as well as the treatment options for COVID-19 comorbid patients from the perspective of ACE2. The efficacies of various clinical chemotherapeutic options, including anti-diabetic drugs, renin-angiotensin-aldosterone system inhibitors, lipid-lowering drugs, anticoagulants, and glucocorticoids for COVID-19 positive diabetic patients were discussed. Moreover, we reviewed the significance of two different forms of ACE2 (mACE2 and sACE2) and gender on COVID-19 susceptibility and severity. This review summarizes COVID-19 pathophysiology and the best strategies for clinical management of diabetes patients with COVID-19.
摘要：
已经评估了糖尿病与COVID-19之间的潜在关系。然而,新知识正在迅速出现。在这项研究中,我们系统地回顾了病毒细胞表面受体(ACE2，AXL，CD147,DC-SIGN,L-SIGN和DPP4）和SARS-CoV-2感染风险，并强调了ACE2对SARS-CoV-2感染和COVID-19发病机制的影响。此外,我们从ACE2的角度更新了糖尿病和COVID-19之间的双向相互作用,以及COVID-19共病患者的治疗方案.各种临床化疗方案的疗效，包括抗糖尿病药物,肾素-血管紧张素-醛固酮系统抑制剂，降脂药物,抗凝剂,讨论了糖皮质激素对COVID-19阳性糖尿病患者的治疗。此外，我们回顾了两种不同形式的ACE2(mACE2和sACE2)和性别对COVID-19易感性和严重程度的影响.本文总结了COVID-19的病理生理学和COVID-19糖尿病患者临床管理的最佳策略。
